Source: Killeen Daily Herald
“Weight-loss drugs like Ozempic and Zepbound might help protect people from health risks related to sleep apnea, a new study says. Type 2 diabetes patients taking GLP-1 drugs were overall less likely to die within the next year, but those with sleep apnea did even better, researchers reported Monday at a meeting of the American College of Chest Physicians in Chicago. … The results support the U.S. Food and Drug Administration’s (FDA) decision in December 2024 to approve Zepbound (tirzepetide) as the first drug to treat sleep apnea in adults with obesity.” (10/21/25)